Mineralys Therapeutics (MLYS) Expected to Announce Earnings on Tuesday

Mineralys Therapeutics (NASDAQ:MLYS) is expected to release its Q2 2025 earnings data after the market closes on Tuesday, August 12th. Analysts expect Mineralys Therapeutics to post earnings of ($0.78) per share for the quarter.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.02) by $0.23. On average, analysts expect Mineralys Therapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Mineralys Therapeutics Trading Up 1.0%

NASDAQ MLYS opened at $13.00 on Monday. The company has a fifty day simple moving average of $14.25 and a 200 day simple moving average of $13.44. The company has a market cap of $847.34 million, a P/E ratio of -3.49 and a beta of -0.29. Mineralys Therapeutics has a 1 year low of $8.24 and a 1 year high of $18.38.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on MLYS shares. Wall Street Zen downgraded shares of Mineralys Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 14th. Guggenheim set a $48.00 price target on shares of Mineralys Therapeutics and gave the company a “buy” rating in a report on Wednesday, May 14th. Jefferies Financial Group started coverage on shares of Mineralys Therapeutics in a report on Tuesday, June 10th. They issued a “hold” rating and a $15.00 price target for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $42.00 price target on shares of Mineralys Therapeutics in a report on Tuesday, June 17th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, Mineralys Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $32.25.

Insider Transactions at Mineralys Therapeutics

In other news, insider David Malcom Rodman sold 11,366 shares of the firm’s stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $15.29, for a total transaction of $173,786.14. Following the completion of the transaction, the insider directly owned 106,669 shares of the company’s stock, valued at approximately $1,630,969.01. This trade represents a 9.63% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Adam Scott Levy sold 59,925 shares of the firm’s stock in a transaction dated Wednesday, July 30th. The stock was sold at an average price of $14.76, for a total transaction of $884,493.00. Following the transaction, the chief financial officer directly owned 132,934 shares of the company’s stock, valued at $1,962,105.84. The trade was a 31.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 123,052 shares of company stock valued at $1,803,099. Company insiders own 33.24% of the company’s stock.

Hedge Funds Weigh In On Mineralys Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in MLYS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Mineralys Therapeutics by 4.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,085 shares of the company’s stock worth $271,000 after purchasing an additional 702 shares in the last quarter. Creative Planning acquired a new stake in shares of Mineralys Therapeutics during the 2nd quarter worth about $336,000. AQR Capital Management LLC acquired a new stake in shares of Mineralys Therapeutics during the 1st quarter worth about $550,000. Woodline Partners LP acquired a new stake in shares of Mineralys Therapeutics during the 1st quarter worth about $757,000. Finally, Goldman Sachs Group Inc. increased its position in shares of Mineralys Therapeutics by 166.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 298,395 shares of the company’s stock worth $4,739,000 after purchasing an additional 186,480 shares in the last quarter. 84.46% of the stock is owned by institutional investors.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.